Pharmaceutical News

RSS

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

Vitamin D may improve exercise capacity, respiratory muscle strength in COPD patients

Vitamin D supplements may help patients with chronic obstructive pulmonary disease (COPD) get more from their pulmonary rehabilitation programs, according to a study conducted by researchers from Belgium.

16 May 2011

Obese men may face high risk of prostate cancer progression

Even when treated with hormone therapy to suppress tumor growth, obese men face an elevated risk of their prostate cancer worsening, researchers at Duke University Medical Center have found.

16 May 2011

Mylan introduces Cyclobenzaprine HCl ER Capsules, a muscle relaxant

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) Capsules, 15 mg and 30 mg. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Cyclobenzaprine HCl ER Capsules and was awarded 180 days of marketing exclusivity.

16 May 2011

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

The U.S. Food and Drug Administration today approved Victrelis (boceprevir) to treat certain adults with chronic hepatitis C. Victrelis is used for patients who still have some liver function, and who either have not been previously treated with drug therapy for their hepatitis C or who have failed such treatment.

16 May 2011

Scientists 'tinker' with HIV drug chemistry hoping to reduce costs

The Clinton Health Access Initiative, founded by former President Bill Clinton, with funding from the Bill & Melinda Gates Foundation and the U.K. government, has hired former pharmaceutical company scientists "to tinker with the chemistry used to synthesize a key [HIV] drug, tenofovir" in an effort to reduce "the cost of manufacturing," the Wall Street Journal reports.

13 May 2011

China's SFDA approves TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets.

13 May 2011

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Risperidone Orally Disintegrating Tablets, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, the generic version of Ortho-McNeil's Risperdal M-Tab, a treatment for schizophrenia.

13 May 2011

Patients with sickle cell disease may require higher, frequent doses of morphine

Frequent episodes of severe pain occur in patients with sickle cell disease (SCD) and require treatment with potent opioid medications. A new study published in The Journal of Pain reports that SCD patients clear morphine from their blood stream quickly and, therefore, require high doses to achieve optimal analgesia.

13 May 2011

Rethink praises Ontario's decision to provide breast cancer patients with access to Herceptin

Today, Rethink Breast Cancer (Rethink) applauds the Ontario government's decision to provide breast cancer patients with tumours less than or equal to 1 cm access to the revolutionary drug Herceptin under the new Evidence Building Program.

13 May 2011

Majority of high-risk heart disease patients have poor adherence to statin treatment

A new study from North Carolina State University shows that the vast majority of patients at high risk for heart disease or stroke do a poor job of taking statins as prescribed. That's especially unfortunate, because the same study shows that taking statins can significantly increase the quality and length of those patients' lives.

13 May 2011

Hydroxyurea safe and effective for infants, toddlers with sickle-cell disease

In what is being hailed as a significant advance in the treatment of children with sickle cell anemia, a drug commonly used to treat adults has been shown to be safe and effective in children.

13 May 2011

Researchers help explain why smart drugs are not effective in some cancer patients

Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor, and found that a decoy receptor might be limiting the amount of drug that gets to the intended target.

12 May 2011

ETI finalizes proprietary progesterone formulations for Traumatic Brain Injury

Encore Therapeutics, Inc. today reported finalizing its proprietary phospholipid nanoemulsion formulation of progesterone.

12 May 2011

Linguamatics releases I2E. Version 3.2 software for pharmaceutical companies

Linguamatics, the leader in NLP-based enterprise text mining for life sciences and other markets, announces the latest release of its award-winning software platform, I2E.

12 May 2011

New organocatalyst now available for drug development industry

A new "organocatalyst" developed at Oregon State University is now available for commercial use. Produced by an Albany, Ore., pharmaceutical company, it should make new drug development around the world less costly, more efficient and more environmentally friendly.

12 May 2011

Health Canada approves EMEND IV formulation to prevent chemotherapy-induced nausea, vomiting

Today Merck announced that Health Canada has approved the new intravenous formulation of EMEND IV. Used in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, fosaprepitant dimeglumine is indicated for the prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.

12 May 2011

Antiretroviral therapy can reduce risk of HIV transmission in couples

When one partner in a couple is infected with HIV and the other is not, treatment with antiretroviral drugs can dramatically lower the chances of the infected partner passing along the disease to his or her mate, a new evidence review finds.

12 May 2011

Losartan therapy improves muscle injury regeneration and prevents disuse atrophy

Using geriatric mice, a Johns Hopkins research team has shown that losartan, a commonly used blood pressure drug, not only improves regeneration of injured muscle but also protects against its wasting away from inactivity.

12 May 2011

Pharmaceutical News

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

Vitamin D may improve exercise capacity, respiratory muscle strength in COPD patients

Obese men may face high risk of prostate cancer progression

Mylan introduces Cyclobenzaprine HCl ER Capsules, a muscle relaxant

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

Scientists 'tinker' with HIV drug chemistry hoping to reduce costs

China's SFDA approves TPI anti-diabetic drug Gliclazide

Mylan introduces Risperidone Orally Disintegrating Tablets for schizophrenia treatment

Patients with sickle cell disease may require higher, frequent doses of morphine

Rethink praises Ontario's decision to provide breast cancer patients with access to Herceptin

Majority of high-risk heart disease patients have poor adherence to statin treatment

Hydroxyurea safe and effective for infants, toddlers with sickle-cell disease

Researchers help explain why smart drugs are not effective in some cancer patients

ETI finalizes proprietary progesterone formulations for Traumatic Brain Injury

Linguamatics releases I2E. Version 3.2 software for pharmaceutical companies

New organocatalyst now available for drug development industry

Health Canada approves EMEND IV formulation to prevent chemotherapy-induced nausea, vomiting

Antiretroviral therapy can reduce risk of HIV transmission in couples

Losartan therapy improves muscle injury regeneration and prevents disuse atrophy

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News